BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/27/2022 2:48:53 AM | Browse: 612 | Download: 1360
Publication Name World Journal of Gastroenterology
Manuscript ID 75160
Country India
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
Manuscript Source Invited Manuscript
All Author List Swati Katoch, Vinesh Sharma and Vikram Patial
ORCID
Author(s) ORCID Number
Swati Katoch http://orcid.org/0000-0001-9120-6327
Vinesh Sharma http://orcid.org/0000-0003-3767-4124
Vikram Patial http://orcid.org/0000-0002-4912-9871
Funding Agency and Grant Number
Funding Agency Grant Number
CSIR, India MLP0204
Corresponding Author Vikram Patial, PhD, Senior Scientist, Division of Dietetics and Nutrition Technology, Institute of Himalayan Bioresource Technology, NA, Palampur 176061, Himachal Pradesh, India. vikrampatial@ihbt.res.in
Key Words Anticancer; Hepatocellular carcinoma; Natural agonists; Peroxisome proliferator-activated receptor-γ; Thiazolidinediones
Core Tip Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Viral infections and metabolic syndrome are the major risk factors for HCC, and its incidence is expected to increase to > 1 million cases annually by 2025. The crucial role of peroxisome-proliferator-activated receptor gamma (PPARγ) in HCC pathophysiology makes it a potential therapeutic target. Along with synthetic agonists, natural PPARγ agonists provide alternative and safer options for HCC treatment; however, they need to be validated clinically. This review discusses the regulatory role of PPARγ in HCC pathogenesis and experimental and clinical scenarios of PPARγ agonists in HCC treatment.
Publish Date 2022-07-27 02:48
Citation Katoch S, Sharma V, Patial V. Peroxisome proliferator-activated receptor-gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios. World J Gastroenterol 2022; 28(28): 3535-3554
URL https://www.wjgnet.com/1007-9327/full/v28/i28/3535.htm
DOI https://dx.doi.org/10.3748/wjg.v28.i28.3535
Full Article (PDF) WJG-28-3535.pdf
Full Article (Word) WJG-28-3535.docx